Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2

ConclusionsUpadacitinib provides rapid, clinically meaningful, and sustained improvements in PROs reported by bDMARD-IR PsA patients. SELECT-PsA 2 ClinicalTrials.gov number, NCT03104374.

http://link.springer.com/10.1007/s40744-021-00377-x

Source: Rheumatology and Therapy - October 18, 2021 Category: Rheumatology Source Type: research